|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0025179,
umls-concept:C0030576,
umls-concept:C0066335,
umls-concept:C0086466,
umls-concept:C0087111,
umls-concept:C0205195,
umls-concept:C0332237,
umls-concept:C1272883,
umls-concept:C1272936,
umls-concept:C1328252,
umls-concept:C1522168,
umls-concept:C1533685
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-6-1
|
|
pubmed:abstractText |
Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/kg.d]). Cohort 1 received topical therapy for 10 days and Sb for 7 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 7-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritus in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1058-4838
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
47-51
|
|
pubmed:dateRevised |
2009-2-26
|
|
pubmed:meshHeading |
pubmed-meshheading:7727669-Administration, Topical,
pubmed-meshheading:7727669-Adolescent,
pubmed-meshheading:7727669-Adult,
pubmed-meshheading:7727669-Animals,
pubmed-meshheading:7727669-Antiprotozoal Agents,
pubmed-meshheading:7727669-Benzethonium,
pubmed-meshheading:7727669-Drug Administration Schedule,
pubmed-meshheading:7727669-Drug Therapy, Combination,
pubmed-meshheading:7727669-Humans,
pubmed-meshheading:7727669-Injections, Intramuscular,
pubmed-meshheading:7727669-Injections, Intravenous,
pubmed-meshheading:7727669-Leishmania braziliensis,
pubmed-meshheading:7727669-Leishmaniasis, Cutaneous,
pubmed-meshheading:7727669-Leishmaniasis, Mucocutaneous,
pubmed-meshheading:7727669-Male,
pubmed-meshheading:7727669-Meglumine,
pubmed-meshheading:7727669-Middle Aged,
pubmed-meshheading:7727669-Organometallic Compounds,
pubmed-meshheading:7727669-Paromomycin
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
|
|
pubmed:affiliation |
Bogota Military Hospital, Colombia.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
